Please Wait...

COL4 // Type IV Collagen

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Type Collagen IV is encoded by six genes: COL4A1, COL4A2, COL4A3, COL4A4, COL4A5, and COL4A6 for the six collagen chain implicated in its composition: α1(IV) through α6(IV). The assembly of collagen IV network is highly regulated. Each of the six chains present the same features with three domains: short 7S N-Terminal, collagenous domain and non-collagenous domain (NC1) in C-terminal and can form three sets of helical molecules. Depending on the tissues the set of collagen type IV molecules is different. The α1.α1.α2(IV)-α1.α1.α2(IV) network is found in all basement membranes in the animal phyla, the α3.α4.α5(IV)-α3.α4.α5(IV) and the α1.α1.α2(IV)-α5.α5.α6(IV) are only found in mammalian basement membranes (Hudson et al., 2003). NC1 trimers also connect to form hexameric quaternary structure through head to head interaction and the collagen IV network is also formed through protomer-protomer interactions in the collagenous and covalent binding in the 7S domain (with four independent protomers)(Cummings and Hudson, 2014). Elevated serum and/or urinary content in Collagen IV can be found in patient with diabetic nephropathy and in some cancers (Banu et al., 1995; KINOSHITA et al., 2010; Nyström et al., 2015).

Bioclinica Lab employs a manual sandwich immunoassay for the measurement of Collagen IV in serum, plasma or urine.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen